Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 9/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17960478 | 0.89 | HDAC6 (0.66) | RIPK1HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL17960224 | 0.88 | RIPK1 (0.50) | RIPK1HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL17960419 | 0.87 | RIPK1 (0.56) | RIPK1HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL17960326 | 0.83 | HDAC6 (0.50) | RIPK1HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL17960436 | 0.82 | HDAC6 (0.48) | RIPK1HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL17960360 | 0.81 | RIPK1 (0.57) | RIPK1HDAC6HDAC8KCNQ2 | |
| SCHEMBL17960332 | 0.81 | HDAC6 (0.49) | RIPK1HDAC6HDAC8 | |
| SCHEMBL17960583 | 0.81 | RIPK1 (0.49) | RIPK1HDAC6HDAC8SMN1; SMN2 | |
| SCHEMBL21800530 | 0.80 | RIPK1 (0.70) | RIPK1 | |
| SCHEMBL17960681 | 0.80 | RIPK1 (0.42) | RIPK1HDAC6HDAC8HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | RIPK1 3548/4885HDAC6 6/4885HDAC8 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.